EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access

Outcome‐Guided Immunosuppressive Therapy and Clinical Events in Patients With Cardiac Sarcoidosis: An Observational Registry

Turid Franziska Ebbinghaus-Holst, Hans Ebbinghaus iD, Laura Ueberham iD, Konrad Latuscynski iD, Ingo Paetsch iD, Cosima Jahnke iD, Joanna Jozwiak-Nozdrzykowska iD, Kerstin Bode iD, Sotirios Nedios iD, Gerhard Hindricks iD, Borislav Dinov iD

Journal of the American Heart Association · 2026

DOI: 10.1161/jaha.126.049395 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Journal of the American Heart Association, 2026. Verfasst von Turid Franziska Ebbinghaus-Holst und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Electrophysiology Helios Heart Center of Leipzig Leipzig Germany. Hauptthemen laut MEDLINE: Cardiomyopathies, Immunosuppressive Agents, Registries, Sarcoidosis. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Immunosuppressive therapy (IST) is commonly used in cardiac sarcoidosis, but the strategy to guide it is unclear and its effectiveness uncertain. We assessed the association between IST, guided by clinical course and positron emission tomography, and clinical outcomes in cardiac sarcoidosis.

Methods

We compared 83 patients with cardiac sarcoidosis who received IST with 20 who declined therapy. IST was escalated for persistent symptoms and inflammation. Ventricular arrhythmia recurrence, ventricular pacing, New York Heart Association class, and left ventricular (LV) ejection fraction were assessed after 12 months. Death, LV assist device, and heart transplantation were assessed during a median follow‐up of 24.9 months.

Results

Sustained ventricular tachycardia recurred in 12% of patients with IST versus 20% of those without IST ( P =0.264). Within the IST group, New York Heart Association class and LV ejection fraction improved during 12 months ( P =0.011 and P =0.002), but the between‐group difference in New York Heart Association change was not significant ( P =0.490). Major adverse cardiovascular events occurred less frequently with IST (10.8% versus 40.0%, P =0.004). After adjustment for baseline LV ejection fraction, IST had a lower hazard of major adverse cardiovascular events (hazard ratio, 0.30 [95% CI, 0.11–0.80]; P =0.017), consistent among sensitivity analyses. Given only 17 events and baseline imbalance, residual confounding cannot be excluded and this is hypothesis‐generating.

Conclusions

In this observational registry, glucocorticoid‐based IST was associated with lower rates of death, heart transplantation, and LV assist device implantation. No significant between‐group difference was detected in sustained ventricular tachycardia recurrence, although the study was underpowered to exclude smaller differences. Because treatment was not randomized, these associations cannot establish causality.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CardiomyopathiesImmunosuppressive AgentsRegistriesSarcoidosisFemaleHumansMaleMiddle AgedHeart TransplantationPositron-Emission TomographyRecurrenceRisk FactorsStroke VolumeTachycardia, VentricularTime FactorsTreatment OutcomeVentricular Function, Left

Stichwörter der Autor:innen

cardiac sarcoidosisimmunosuppressive therapymortalityventricular tachyarrhythmia

Substanzen

Immunosuppressive Agents

Autor:innen und Institutionen

  • Department of Electrophysiology Helios Heart Center of Leipzig Leipzig Germany.
  • Department of Cardiology Hospital St. Georg Leipzig Germany.
  • Department of Cardiology University Hospital of Leipzig Leipzig Germany.
  • DHZ Charite Berlin Germany.
  • Department of Cardiology and Angiology University Hospital of Giessen, UKGM Giessen Germany.

ORCID-Profile: Hans Ebbinghaus, Laura Ueberham, Konrad Latuscynski, Ingo Paetsch, Cosima Jahnke, Joanna Jozwiak-Nozdrzykowska, Kerstin Bode, Sotirios Nedios, Gerhard Hindricks, Borislav Dinov

Zitieren

APA

Ebbinghaus-Holst, T. F., Ebbinghaus, H., Ueberham, L., Latuscynski, K., Paetsch, I., Jahnke, C., Jozwiak-Nozdrzykowska, J., Bode, K., Nedios, S., Hindricks, G., & Dinov, B. (2026). Outcome‐Guided Immunosuppressive Therapy and Clinical Events in Patients With Cardiac Sarcoidosis: An Observational Registry. Journal of the American Heart Association. https://doi.org/10.1161/jaha.126.049395

Vancouver

Ebbinghaus-Holst TF, Ebbinghaus H, Ueberham L, Latuscynski K, Paetsch I, Jahnke C, et al. Outcome‐Guided Immunosuppressive Therapy and Clinical Events in Patients With Cardiac Sarcoidosis: An Observational Registry. Journal of the American Heart Association. 2026. doi:10.1161/jaha.126.049395

BibTeX
@article{EbbinghausHolst2026,
  author = {Ebbinghaus-Holst, Turid Franziska and Ebbinghaus, Hans and Ueberham, Laura and Latuscynski, Konrad and Paetsch, Ingo and Jahnke, Cosima and Jozwiak-Nozdrzykowska, Joanna and Bode, Kerstin and Nedios, Sotirios and Hindricks, Gerhard and Dinov, Borislav},
  title = {Outcome‐Guided Immunosuppressive Therapy and Clinical Events in Patients With Cardiac Sarcoidosis: An Observational Registry},
  journal = {Journal of the American Heart Association},
  year = {2026},
  doi = {10.1161/jaha.126.049395}
}
Kostenlos starten →